Clinical Trial ECOG 2607
- A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas
- Principal Investigator
- Timothy Kuzel
- Status: COMPLETED
- Study Type: Therapeutic, Treatment
- Protocol No:.ECOG 2607
- The purpose of this study is to find out what effects, good and/or bad, dasatinib has on patients and on melanoma cancer.
- Dasatinib is approved by the Food and Drug Administration (FDA) for patients with leukemia, which is a type of blood cancer. The use of dasatinib is not approved for the treatment of melanoma, and therefore, is considered experimental for this treatment. Dasatinib is not chemotherapy but is an oral medication which targets proteins that are thought to be present on the melanoma cancer cells.
Some of the eligibility criteria include:
- Participants must be 18 years old or older.
- Participants must have a diagnosis of metastatic melanoma (melanoma that has spread beyond the original site of the disease) or unresectable melanoma (it cannot be removed with surgery).
- Participants with previous treatments are allowed to participate.
- Description of Treatment
- Participants will take dasatinib by mouth twice a day for 42 days along with their standard care treatment.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
last updated: 22-Feb-17 04:00 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.